Information regarding Active Biotech's candidate drug laquinimod
(Thomson Reuters ONE) -
Lund November 2, 2011 - During Teva's 3(rd) Quarter 2011 Results Conference Call
today, Teva's CEO Shlomo Yanai commented "Last week we held a meeting with the
FDA to discuss the NDA for laquinimod. Following the meeting we now believe that
it would be premature to file NDA at this time. The FDA has offered to work with
us to determine the best design for conducting an additional trial".
Active Biotech AB (publ)
Tomas Leanderson
President & CEO
For further information, please contact
Tomas Leanderson, President & CEO
Tel: +46 46 19 20 95
tomas.leanderson(at)activebiotech.com
ABOUT ACTIVE BIOTECH
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in or entering
pivotal phase are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, TASQ for
prostate cancer as well as ANYARA for use in cancer targeted therapy, primarily
of renal cell cancer. In addition, laquinimod is in Phase II development for
Crohn's and Lupus. Further projects in clinical development comprise the two
orally administered compounds, 57-57 for SLE & Systemic Sclerosis and RhuDex(TM)
for RA. Please visit www.activebiotech.com for more information.
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00
Active Biotech is required under the Securities Markets Act to make the
information in this press release public. The information was submitted for
publication at 14:30 a.m. CET on November 2, 2011.
Information regarding Active Biotech?s candidate drug laquinimod:
http://hugin.info/1002/R/1560205/482628.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Active Biotech via Thomson Reuters ONE
[HUG#1560205]
Unternehmensinformation / Kurzprofil:
Datum: 02.11.2011 - 15:19 Uhr
Sprache: Deutsch
News-ID 83170
Anzahl Zeichen: 2573
contact information:
Town:
LUND
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 210 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Information regarding Active Biotech's candidate drug laquinimod"
steht unter der journalistisch-redaktionellen Verantwortung von
Active Biotech (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
